Genetic polymorphisms of cytochrome CYP2C9 in the Czech population;Genetický polymorfismus cytochromu CYP2C9 v české populaci

Klinicka Biochemie a Metabolismus

Volumn 15, Issue 2, 2007, Pages 102-105

  Buzková, Helena ^a   Pechandova K ^a   Slanar O ^a   Perlik F ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

CYP2C9; Cytochrome P450; Czech population; Pharmacogenetics; Polymorphism

Indexed keywords

EID: 67651173452     PISSN: 12107921     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Inoue, K., Yamazaki, H., Imiya, K. et al. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics, 1997, 7, 2, p. 103-113.
2. Schwarz, U. I. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur. J. Clin. Invest., 2003, 33, Suppl 2, p. 23-30.
3. Goldstein, J. A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol., 2001, 52, 4, p. 349-355.
4. Kirchheiner, J., Brockmoller, J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther., 2005, 77, 1, p. 1-16.
5. Aynacioglu, A. S., Brockmoller, J., Bauer, S. et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br. J. Clin. Pharmacol., 1999, 48, 3, p. 409-415.
6. Freytag, G. Die Bedeutung genetischer Polymorphismen im Enzym Cytochrom P450 2C9 fur Pharmakokinetik und Wirkungen der Nichtsteroidalen Antiphlogistika Diclofenac und Ibuprofen. Berlin : Medizinischen Fakultat der Charite, 34 s.
7. Bozina, N., Granic, P., Lalic, Z. et al. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat. Med. J., 2003, 44, 4, p. 425-428.
8. Dorado, P., Berecz, R., Norberto, M. J. et al. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur. J. Clin. Pharmacol., 2003, 59, 3, p. 221-225.
9. Yang, J. Q., Morin, S., Verstuyft, C. et al. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam. Clin. Pharmacol., 2003, 17, 3, p. 373-376.
10. Stubbins, M. J., Harries, L. W., Smith, G., Tarbit, M. H., Wolf, C. R. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics, 1996, 6, 5, p. 429-439.
11. Yasar, U., Lundgren, S., Eliasson, E. et al. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem. Biophys. Res. Commun., 2002, 299, 1, p. 25-28. (Pubitemid 35366030)
12. Scordo, M. G., Caputi, A. P., D'Arrigo, C., Fava, G., Spina, E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol. Res., 2004, 50, 2, p. 195-200.
13. Gaikovitch, E. A., Cascorbi, I., Mrozikiewicz, P. M. et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur. J. Clin. Pharmacol., 2003, 59, 4, p. 303-312.
14. Scordo, M. G., Aklillu, E., Yasar, U. et al. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br. J. Clin. Pharmacol., 2001, 52, 4, p. 447-450.
15. Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A. et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 1996, 6, 4, p. 341-349.
16. Wood, A. J. Racial differences in the response to drugs - pointers to genetic differences. N. Engl. J. Med., 2001, 344, 18, p. 1394-1396.
17. Aithal, G. P., Day, C. P., Kesteven, P. J., Daly, A. K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353, 9154, p. 717-719.
18. Higashi, M. K., Veenstra, D. L., Kondo, L. M. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Jama, 2002, 287, 13, p. 1690-1698.
19. Kirchheiner, J., Stormer, E., Meisel, C., et al. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics, 2003, 13, 8, p. 473-480.
20. Rodrigues, A. D. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab. Dispos., 2005, 33, 11, p. 1567-1575.
21. Kirchheiner, J., Kudlicz, D., Meisel, C. et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5Sfluvastatin in healthy volunteers. Clin. Pharmacol. Ther., 2003, 74, 2, p. 186-194.